<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selection of multiple myeloma therapy at third or later relapse</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selection of multiple myeloma therapy at third or later relapse</h1>
<div class="graphic"><div class="figure"><div class="ttl">Selection of multiple myeloma therapy at third or later relapse</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">There is no single standard therapy for relapsed or refractory MM and practice varies widely; as such, we encourage eligible patients to participate in clinical trials. This algorithm illustrates our approach to systemic therapy in patients with third or greater relapse of MM. Other regimens are available and may be used by other experts. The choice for an individual must take into account expected toxicities, comorbidities, and drug accessibility.</div><div class="graphic_footnotes"><p>BCMA: B cell maturation antigen; CAR: chimeric antigen receptor; Cilta-cel: ciltacabtagene autoleucel; DCEP: dexamethasone, cyclophosphamide, etoposide, and cisplatin; Ide-cel: idecabtagene vicleucel; MM: multiple myeloma; VDT-PACE: bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide.</p>
* We use the following cutoffs to define refractory and not refractory MM to guide therapy:
<ul>
<li>Refractory: Progression within 60 days of exposure to an agent at standard doses</li>
<li>Sensitive: Progression &gt;60 days from last exposure or progression on minimal therapy (eg, lenalidomide 10 mg or monthly daratumumab)</li>
</ul>
<p class="extra_spacing">¶ When selecting a regimen, avoid agents that the MM is refractory to and prioritize regimens that contain two drugs that the MM has not been exposed to.</p>
Δ Options include CAR-T cell therapy (ide-cel or cilta-cel) or a BCMA/CD3 bispecific antibody (teclistamab or elranatamab). A choice is individualized weighing disease tempo, availability, and expected toxicity. As an off-the-shelf option, bispecific antibodies may be preferred in rapidly progressing disease unlikely to be controlled while awaiting CAR-T cell manufacturing.</div><div id="graphicVersion">Graphic 134484 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
